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Objectives. A general body of evidence suggests that low serum albumin might be associated with increased 
risk of adverse cardiometabolic outcomes, but findings are divergent. We aimed to quantify associations of 
serum albumin with the risk of type 2 diabetes (T2D), cardiovascular disease (CVD), all-cause mortality, and 
other adverse outcomes using a systematic review and meta-analyses of published observational cohort 
studies. Design. MEDLINE, Embase, Web of Science, and manual search of relevant bibliographies were 
systematically searched to January 2020. Relative risks (RRs) with 95% confidence intervals (CIs) comparing 
top versus bottom thirds of serum albumin levels were pooled. Results. Fifty-four articles based on 48 unique 
observational cohort studies comprising of 1,492,237 participants were eligible. Multivariable adjusted RRs 
(95% CIs) comparing the top vs bottom third of serum albumin levels were: 1.03 (0.86-1.22) for T2D; 0.60 
(0.53-0.67) for CVD; 0.74 (0.66-0.84) for coronary heart disease (CHD); 0.57 (0.36-0.91) for CHD death; 
0.76 (0.65-0.87) for myocardial infarction; 0.66 (0.55-0.77) for all-cause mortality; 0.71 (0.61-0.83) for 
venous thromboembolism; 0.65 (0.48-0.88) for cancer mortality; and 0.62 (0.46-0.84) for fracture. 
Heterogeneity between contributing studies of T2D was partly explained by sample sizes of studies (p for 
meta-regression=0.035). Conclusions. Elevated levels of serum albumin are associated with reduced risk of 
vascular outcomes, all-cause mortality, certain cancers, and fracture. Inconsistent findings for T2D may be 
attributed to selective reporting by studies. Further research is needed to assess any potential causal relevance 
to these findings and the role of serum albumin concentrations in disease prevention. 
Systematic review registration: PROSPERO 2019: CRD42019125869 
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Serum albumin, a protein which is synthesized in the liver,[1] is a historical marker of nutritional status.[2] 
Serum albumin has antioxidative properties[3] and low serum concentrations have been suggested to be an 
indicator of inflammation, hypercoagulable states and liver disease.[4, 5] Serum albumin concentrations have 
been demonstrated to be inversely correlated with several risk factors for cardiometabolic disease such as age, 
total cholesterol, body mass index (BMI), and inflammatory markers.[6, 7, 8] Evidence suggests that serum 
albumin concentrations may be associated with a wide range of cardiometabolic outcomes including 
cardiovascular disease (CVD),[4, 9, 10] type 2 diabetes,[11, 12] metabolic syndrome,[13, 14],  and all-cause 
mortality.[9] Though the general body of evidence suggests low serum albumin is associated with increased 
risk of these adverse outcomes; some of the findings have not been consistent. For example, on the 
relationship between serum albumin and type 2 diabetes; whereas some studies have demonstrated inverse 
associations,[11, 12]  others have reported positive associations,[15] and some others have found no 
associations.[8, 12] Several reasons could explain the conflicting results and could be related to study design 
factors such as small sample sizes (low event rates).[15] Furthermore, some previous studies were based on 
cross-sectional designs,[13, 14] hence the temporal nature of the associations is limited. Though established 
risk factors explain a large proportion of the risk for these adverse cardiometabolic outcomes, their 
pathogeneses are still not fully established as it appears other additional factors may be involved. There is 
therefore a priority to identify and evaluate potentially modifiable risk factors that may have predictive or 
causal relevance, to help tailor preventive and therapeutic strategies for these conditions. Serum albumin is 
such a biomarker which has potential promise for the prevention of adverse cardiometabolic outcomes. Given 
that individual studies are often poorly powered and their results are not always definitive, we sought to 
quantify the nature, magnitude and specificity of potential longitudinal associations of serum albumin with the 
risk of adverse cardiometabolic outcomes such as type 2 diabetes, CVD, metabolic syndrome, and all-cause 
mortality in more detail than ever before using a systematic review and meta-analysis of available 
observational cohort studies. In subsidiary analyses, we also explored associations with other adverse health 





Data sources, searches and screening 
This review has been registered in the PROSPERO prospective register of systematic reviews 
(CRD42019125869). The systematic review and meta-analysis was based on a predefined protocol and 
conducted in accordance with PRISMA and MOOSE guidelines [16, 17] (Supplementary Tables 1-2). 
MEDLINE and Embase were searched from inception to 30 January 2020. The computer-based searches used 
a combination of MeSH terms related to the exposure (e.g., serum albumin) and outcomes (e.g., 
cardiovascular disease, type 2 diabetes, mortality) in humans with no language restrictions. The detailed 
search strategy is reported in Supplementary Table 3. The titles and abstracts of citations identified from the 
databases were then initially screened to identify articles potentially eligible for inclusion. Following this, full 
texts of relevant articles were acquired for further evaluation. The full text evaluation was independently 
conducted by two authors (SKK and SS) based on the inclusion criteria indicated below. Any disagreements 
regarding eligibility of an article was discussed, with involvement of a third author when necessary (KK). 
Reference lists of relevant studies and the “cited by” function in Web of Science were assessed to identify 
additional studies missed by the search strategy. 
 
Eligibility criteria 
Studies were included if they met the following search criteria: were population-based observational 
(prospective or retrospective cohort, case cohort, or nested case-control) in design; had sampled from healthy 
(i.e., were based on initially healthy participants) or general populations (ie, populations with both healthy and 
prevalent cases of cardiometabolic disease at baseline); had evaluated the associations of circulating albumin 
concentrations with primary and secondary outcomes; and had at least one year of follow-up. The primary 
outcomes were cardiometabolic outcomes and included CVD (including cardiovascular endpoints such as 
coronary heart disease (CHD), myocardial infarction (MI), and stroke), type 2 diabetes, metabolic syndrome, 
and all-cause mortality. Secondary outcomes were other cardiometabolic and nonvascular outcomes including 
hypertension, heart failure, venous thromboembolism, dementia, cancer and fracture. We excluded studies for 
the following reasons: (i) they only reported on mean levels and standard deviations of serum albumin in cases 
and non-cases; (ii) were based exclusively in participants with pre-existing cardiometabolic disease; or (iii) 




Data extraction and quality assessment  
One author (SKK) initially extracted data from eligible studies using a standardized predesigned data 
collection form, which has been used in previous similar reviews.[18, 19] A second author (SS) independently 
checked the extracted data with that in original articles. Data were extracted for the following study 
characteristics: author and year of publication, country of study, baseline year of study, study design, age, sex, 
assay type, type of outcome, sample size and number of outcomes, duration of follow-up, degree of 
adjustment for potential confounders [defined as ‘+’ (when risk estimates were adjusted for age and/or sex); 
‘++’ (further adjustment for established risk factors such as smoking status, body mass index, blood pressure, 
lipids); and ‘+++’ (additional adjustment for emerging risk factors such as inflammatory markers)], and risk 
estimates reported for greatest adjustment for potential confounders. To avoid double counting of participants 
within a study cohort, study selection was limited to a single set of comprehensive information when there 
were several publications involving the same study cohort. Selection was based on the study with the most up-
to-date information (longest follow-up duration and/or analysis covering the largest number of participants). 
Methodological quality of studies was assessed using the nine-star Newcastle–Ottawa Scale (NOS),[20] which 
uses pre-defined criteria namely: selection (population representativeness), comparability (adjustment for 
confounders), and ascertainment of outcome. Nine points on the NOS reflects the highest study quality.  
 
Data synthesis and analysis 
Summary measures of associations were presented as relative risks (RRs) with 95% confidence intervals 
(CIs). To enable consistency in the pooling approach and enhance interpretation of the findings, RR estimates 
for the associations of serum albumin and outcomes were transformed to consistently correspond to the 
comparison of the top versus bottom third of the distribution of serum albumin levels in each study, using 
standard statistical methods previously described [19, 21] (Supplementary Table 4). Briefly, log risk 
estimates were transformed assuming a normal distribution (or that a transformation of the exposure variable 
for which the risk ratio is based was normally distributed), with the comparison between top and bottom thirds 
being equivalent to 2.18 times the log risk ratio for a 1 standard deviation increase (or equivalently, as 
2.18/2.54 times the log risk ratio for a comparison of extreme quarters and as 2.18/2.80 times the log risk ratio 
 
 
for a comparison of extreme quintiles). Standard errors of the log risk estimates were calculated using reported 
confidence intervals and were standardised in the same way. For estimates that could not be transformed, the 
top versus bottom categories were used as reported in the included studies. We have shown that pooled 
estimates from transformed and untransformed data are qualitatively similar.[22] When the highest quantile 
(eg, top third) was used as the referent, we converted the reported risk estimate into its reciprocal. When 
studies reported more than one estimate of an association according to subgroups (e.g., by sex), a within-study 
summary estimate was calculated using a fixed effect meta-analysis. Random-effects models were used to 
combine RRs to account for the effect of heterogeneity.[23] Heterogeneity between studies was assessed using 
the standard χ2 statistic and the I2 statistic.[24] We assessed heterogeneity between cohorts by comparing 
results from studies grouped according to prespecified study level characteristics such as geographical 
location, sex, average age at baseline, average duration of follow-up, number of outcomes recorded, degree of 
statistical adjustment, and study quality using random effects meta-regression.[25] We assessed for evidence 
of publication bias using visual inspection of Begg’s funnel plots[26] and Egger’s regression symmetry 
tests.[27] All analyses were conducted using Stata MP 16 (Stata Corp, College Station, Texas, USA).   
 
Results 
Study identification and selection 
The study selection process is illustrated in Figure 1. The initial search as well as the manual screening of 
relevant citations identified 2,886 potentially relevant citations. After screening of citations based on titles and 
abstracts, 77 citations were selected for full text evaluation. A total of 23 articles were excluded because (i) 
exposure was not relevant (n=11); (ii) study design not relevant (n=4); (iii) duplicate of a previous publication 
using the same cohort (n=4); (iv) outcome not relevant (n=3 ); and (v) risk estimates could not be calculated 
(n=1). In total, we included 54 articles based on 48 unique observational cohort studies.[5, 6, 8, 9, 10, 11, 12, 
15, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 
56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73] 
 
Study characteristics and quality 
 
 
Table 1 summarizes characteristics and quality assessment scores of each of the eligible studies evaluating the 
associations between serum albumin and risk of several outcomes. Publication dates of eligible studies ranged 
from 1990 to 2020. Overall, the 48 unique cohorts comprised of 1,492,237 participants. The majority of 
studies were based on prospective cohort designs (n=37), with the remainder based on retrospective cohort 
(n=4), nested case-control (n=4), and case-cohort (n=3) designs. Overall, 19 studies were conducted in North 
America (USA), 17 in Europe (Austria, Finland, France, Germany, Netherlands, Norway, Russia, Spain, 
Sweden, and UK), and 12 in Asia (China, Japan, Korea, and Taiwan). Overall, the average baseline age of 
participants in the included studies ranged from 37.6 to 97.0 years and the weighted mean age was 50.9 years. 
The average overall duration of follow-up for outcomes ranged from 1.0 to 28.5 years, with a weighted mean 
follow-up duration of 8.8 years. For studies providing these data, the overall average serum albumin level 
ranged from 37.3 to 51.0 g/l with a weighted mean of 42.7 g/l. The overall methodological quality scores of 
studies using NOS ranged from 5 to 9.  
 
Serum albumin and risk of primary outcomes 
Figure 2 provides a summary of meta-analyses of the associations between serum albumin and risk of the 
primary and secondary outcomes evaluated. In meta-analysis of 9 studies,[8, 11, 12, 15, 54, 66, 68, 73] 
comparing the top versus bottom third of serum albumin levels, the pooled fully-adjusted RR (95% CI) of 
type 2 diabetes was 1.03 (0.86-1.22) (Figure 3). There was significant heterogeneity between contributing 
studies (I2 =68%; 95% CI 33, 85%; p for heterogeneity<0.001), which seemed to be partly explained by the 
sample size (p for meta-regression=0.04). Smaller studies were more likely to report more extreme results 
compared with larger studies (Supplementary Figure 1). In meta-analyses of cardiovascular outcomes, RRs 
(95% CIs) were 0.60 (0.53-0.67; I2 =22%; 95% CI 0, 66%; p for heterogeneity=0.27, n=6 studies[38, 42, 52, 
62, 71, 74]) for CVD;  0.74 (0.66-0.84; I2 =59%; 95% CI 5, 82%; p for heterogeneity=0.02, n=7 studies[10, 
30, 35, 38, 42, 69, 74]) for CHD; 0.57 (0.36-0.91; I2 =51%; 95% CI 0, 86%; p for heterogeneity=0.13, n=3 
studies[30, 35, 38]) for CHD mortality; 0.76 (0.65-0.87; I2 =0%; 95% CI 0, 85%; p for heterogeneity =0.59, 
n=4 studies[9, 30, 48, 58]) for MI; and 0.99 (0.60-1.63; I2 =91%; 95% CI 75, 96%; p for heterogeneity<0.001, 
n=3 studies[33, 42, 58]) for stroke comparing top versus bottom thirds of serum albumin levels (Figure 2; 
Supplementary Figure 2). Comparing the top versus bottom thirds of serum albumin levels in 21 studies, the 
 
 
pooled RR (95% CI) for all-cause mortality was 0.65 (0.55-0.77) with substantial heterogeneity between 
contributing studies (I2 =97%; 95% CI 96, 97%; p for heterogeneity<0.001) (Figure 4), which seemed to be 
explained partly by the duration of follow-up (p for meta-regression=0.023). The association was stronger for 
studies with shorter follow-up duration (<10 years) compared with studies of longer follow-up duration (≥10 
years) (Supplementary Figure 3). In meta-analysis of 3 studies that compared hypoalbuminaemia versus 
normal albumin,[37, 43, 50] the RR (95% CI) for all-cause mortality was 1.31 (0.86-1.98; I2 =67%; 95% CI 0, 
91%; p for heterogeneity=0.05) (Supplementary Figure 4). Results from single reports showed a decreased 
risk of ischaemic stroke,[58] SCD,[48] and non-SCD[48] comparing the top versus bottom tertile of serum 
albumin levels; whereas the risk of MetS[60] and stroke mortality[33] was increased (Supplementary Figure 
5). Three studies could not be included in the pooled analyses due to the inconsistent reporting of and lack of 
complete data on risk estimates.[29, 45, 64] Darne et al.[29] in their report published in 1990, showed that 
serum albumin was not significantly associated with cardiovascular, cancer, and all-cause mortality. In the 
prospective study of the associations of biomarkers of inflammation and malnutrition with the risk of death in 
health elderly people, Carriere and colleagues showed that low serum albumin was associated with early death 
in men; no associations were demonstrated for women.[45] In patients without pre-existing cardiovascular 
diagnoses, Hayward and colleagues demonstrated low serum albumin to be associated with an increased risk 
of cardiac events.[64] 
 
Serum albumin and risk of secondary outcomes 
In meta-analysis of 4 studies,[5, 6, 57] comparing the top versus bottom third of serum albumin levels, the 
pooled RR (95% CI) of VTE was 0.71 (0.61-0.83; I2 =0%; 95% CI 0, 85%; p for heterogeneity=0.41) (Figure 
2; Supplementary Figure 6). In meta-analyses of cancer endpoints, RRs (95% CIs) were 0.65 (0.48-0.88, I2 
=79%; 95% CI 44, 92%; p for heterogeneity=0.003, n=4 studies[42, 62, 65, 71]) for cancer mortality and 0.92 
(0.85-1.00, I2 =0%; 95% CI 0, 0%; p for heterogeneity=0.76, n=3 studies[39, 63, 65]) for colorectal cancer 
comparing top versus bottom thirds of serum albumin (Supplementary Figure 7). The corresponding RR 
(95% CI) for fracture in meta-analysis of two studies[36, 72] was 0.62 (0.46-0.84) (Supplementary Figure 
8). Findings from single reports showed a decreased risk of heart failure,[49] hypertension,[56] breast 
cancer,[65] colorectal cancer death,[63] and colon cancer;[34] an increased risk of ovarian cancer[67] and no 
 
 
significant associations with all-cause cancer,[38] lung cancer,[65] and prostate cancer[65] (Supplementary 
Figure 8). In single studies that compared hypoalbuminaemia with normal albumin levels, the risk was 
increased for heart failure,[50] cancer,[61] and mild cognitive impairment[70] (Supplementary Figure 9). 
 
Publication bias 
Though tests of publication bias have low power and are unreliable in meta-analysis involving <10 
studies,[75] we assessed for publication bias among studies of type 2 diabetes as the results of the subgroup 
analysis suggested evidence of selective reporting (small study effects) (Supplementary Figure 1). There 
was no evidence of publication bias across studies of type 2 diabetes, with the funnel plot showing no 
evidence of asymmetry (Supplementary Figure 10) and Egger’s test for bias giving a p-value of 0.72. A 
funnel plot of the 21 studies reporting on the associations between serum albumin and all-cause mortality risk 
showed visual evidence of symmetry (Supplementary Figure 10) which was consistent with Egger’s 
regression symmetry test (p=0.34). We also found no evidence of such selective reporting when studies were 
grouped by sample size in meta-regression analysis (i.e., results were similar for smaller and larger studies) 




These meta-analyses on the associations between serum albumin and several adverse outcomes indicates that 
elevated circulating levels of serum albumin in approximately healthy people are associated with reduced risk 
of CVD endpoints (including composite CVD, CHD, MI, SCD, and heart failure), all-cause mortality, 
hypertension, VTE, cancer mortality, breast cancer, colon cancer, colorectal cancer, and fracture. The risk was 
however increased for MetS and ovarian cancer. There were no significant associations with type 2 diabetes, 
lung cancer, and prostate cancer. The association of serum albumin with type 2 diabetes seemed to be 
modified by sample size; smaller studies were more likely to report more extreme results compared with 
larger studies, though the associations were not significant. Furthermore, our findings suggested that the 
association between serum albumin and all-cause mortality risk may be modified by the duration of follow-up, 




Comparison with previous work  
In a previous meta-analysis published over two decades ago, Danesh and colleagues demonstrated low levels 
of serum albumin to be associated with increased risk of CHD in pooled analysis of eight studies. To our 
knowledge, this review represents the first comprehensive evaluation of aggregate observational cohort data 
on the associations of serum albumin with several cardiometabolic and other adverse health outcomes. Being 
the first attempt at doing this, these findings cannot directly be compared to previous work. Though generally 
mounting evidence has suggested that low levels of serum albumin are associated with increased risk of 
cardiometabolic outcomes such as type 2 diabetes, MetS, and CVD (and vice versa), the evidence has been 
inconsistent in the absence of meta-analyses of the existing data. The current study therefore establishes 
robust observational associations of serum albumin with the risk of several adverse outcomes.  
 
Possible explanations for findings 
Several plausible biological pathways might underlie some of the associations demonstrated. It is well 
established that inflammatory processes are involved in the aetiopathogenesis of vascular disease.[76, 77] 
Indeed, several “downstream” and “upstream” markers of inflammation such as C-reactive protein (CRP), 
fibrinogen, interleukins, and tumour necrosis factor alpha (TNF-α) have been demonstrated to be associated 
with the risk of CHD.[78, 79, 80] Serum albumin is a negative acute phase reactant and is synthesized by the 
liver. In the presence of systemic inflammation, there is hepatic synthesis of other acute-phase proteins rather 
than serum albumin.[81] Hence, it has been suggested that low serum albumin levels may reflect 
inflammatory states,[5] which underlie the pathogenesis of vascular disease. Since an inflammatory 
hypothesis has also been postulated in the development of VTE[82]  and other outcomes such as all-cause 
mortality, hypertension, cancer, and fracture,[83]  these same inflammatory processes may explain the 
observational relationships observed. However, since some of the observed associations between serum 
albumin and outcomes were independent of inflammatory markers such as CRP, interleukins, and TNF-α, it is 
likely that other pathways may be involved apart from inflammation. Low serum albumin may be a marker of 
a hypercoagulable state[5] and an indicator of health conditions such as liver disease, nephrotic syndrome, and 
malignancy, which increase the risk of VTE.[84, 85, 86, 87] Low serum albumin is also an indicator of poor 
 
 
nutrition,[2] functional decline,[88, 89, 90] and frailty,[37, 91] which all predispose to an increased risk of 
fractures. Oxidative stress, insulin resistance, and endothelial dysfunction in addition to inflammation, have 
been implicated in the development of hypertension; [92, 93] serum albumin has antioxidant properties[94] 
and also inhibits endothelial apoptosis,[95] hence high levels of serum albumin may protect against the 
development of hypertension. The potent antioxidant activity of serum albumin may contribute to its 
protective role on cancer risk. There were differential effects of albumin levels on the risk of site-specific 
cancers, which may reflect the fact that different types of cancer do not have the same pathogenic process. 
Whether higher serum albumin predisposes to an increased risk of MetS and ovarian cancer or is a marker of 
these adverse outcomes is unclear. The increased risk of ovarian cancer associated with increased serum 
albumin is unexpected given that ovarian cancer is associated with low serum albumin levels.[96] Schwartz 
and colleagues[67] speculate that elevated serum albumin could increase ovarian cancer risk by delivering 
higher levels of hormones to ovarian tissue, since steroid hormones in blood are bound to albumin. The 
authors also report that these findings may reflect increased albumin synthesis by ovarian cells.[67] With the 
inconsistent findings reported for the association between serum albumin and type 2 diabetes in individual 
studies, pooled analysis showed no evidence of an association. These findings were unexpected given the 
plausible pathways underlying the associations between serum albumin and adverse cardiometabolic 
outcomes, which suggest that serum albumin might reduce the risk of type 2 diabetes. Indeed, two of the 
included studies evaluated the associations between serum albumin change during follow-up and type 2 
diabetes risk and observed that an increase in serum albumin during follow-up reduces the risk of type 2 
diabetes.[68, 73] Though there was no evidence of publication bias using formal tests, subgroup analyses 
suggested the current findings might due to selective reporting of studies (small study effects). It is well 
established that due to ageing, changes in lifestyle, chronic disease, and errors in exposure assessments, using 
baseline measurements of an exposure could underestimate the true strength of an association between an 
exposure and disease outcome due to the phenomenon of regression dilution bias.[97] Since our analyses were 
based on baseline serum albumin concentrations, the pooled estimates could be underestimates. In addition, 
given the substantial heterogeneity between contributing studies for type 2 diabetes which may be explained 
by factors such as differences in population characteristics (race, sex, genetic background, and underlying 
subclinical disease) and study design characteristics (blood sampling, assays for serum albumin measurement, 
 
 
or confounder adjustment), these findings need careful interpretation and replication in future studies. Finally, 
evidence of effect modification by follow-up duration on the serum albumin-mortality association might 
reflect protein degradation between sample collection and assay measurements for serum albumin. Serum 
samples for determination of albumin were stored at low temperatures (-20℃ or less) for several years by 
some of the studies and this could have affected the recovery rates of albumin. 
  
Implications of findings 
Although the associations demonstrated do not establish causality for any of the outcomes assessed, the 
comprehensive evaluation helps to bridge the gaps in translating basic scientific findings into clinical practice. 
Serum albumin is a simple, standardised, cost-effective and scalable biomarker which may represent a 
potential therapeutic target for the prevention of adverse cardiometabolic outcomes – increasing or avoiding 
low serum albumin levels could be a strategy for reducing the risk of these health outcomes.  A number of 
randomized controlled trials in surgery have demonstrated that nutritional supplementation is associated with 
reduced risk of complications such as fracture.[98, 99] Studies are needed to ascertain if the current findings 
have any causal relevance (Mendelian randomization) and definitive trials are also needed to investigate 
potential therapeutic implications of albumin supplementation.  
 
 
Strengths and limitations  
This study has several strengths. This represents the first attempt at summarising the overall evidence on the 
associations of serum albumin with multiple outcomes using meta-analyses. We only included studies that had 
exclusively recruited participants from general populations, thereby potentially minimizing any ‘reverse-
causation’ effects of clinically evident pre-existing disease on serum albumin levels. Though there was 
inconsistent reporting of risk comparisons by included studies, we were able to standardise and harmonise risk 
estimates to a common scale (extreme tertiles) to ensure consistency in the pooling approach. Other strengths 
included assessment of exploration of heterogeneity and evaluation for publication bias where possible. Our 
review also had potential limitations. First, some of the findings were based on single or limited number of 
reports and hence require replication in future studies. Second, we were unable to perform consistent 
 
 
multivariate adjustments by combining models with the same set of potential confounders owing to the reliance 
on published data with variable degrees of adjustments across eligible studies. Third, we were unable to correct 
the estimates for within-person variation in serum albumin levels over time which may have underestimated 
associations, because the majority of studies evaluated associations using baseline levels of serum albumin. It 
has been reported that serum albumin may exhibit low within-individual variation (the correlation coefficient 
between measured levels of serum albumin several years apart is approximately 0.70 [1]); however, studies 
with repeat assessments of serum albumin are still needed to assess its variability in greater detail. Fourth, 
given the substantial heterogeneity between contributing studies for some of the outcomes (type 2 diabetes 
and all-cause mortality), it was arguable whether a summary risk estimate should be presented rather than 
reporting estimates in relevant subgroups. The presence of substantial heterogeneity makes pooling of risk 
estimates somewhat controversial; however, in addition to the summary risk estimate, we have also reported 
risk estimates for the several subgroups assessed although little of the heterogeneity was explained by any of 
these study characteristics. 
 
Conclusion 
This aggregate systematic review and meta-analyses of long-term observational cohort studies involving 
apparently healthy adults shows that elevated levels of circulating serum albumin are associated with reduced 
risk of vascular disease, all-cause mortality, hypertension, VTE, certain cancers, and fracture. Inconsistent 
findings for type 2 diabetes may be attributed to selective reporting by studies. Further research is needed to 
assess any potential causal relevance to some of these findings and the role of serum albumin concentrations 
in disease prevention. 
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Figure 1. PRISMA flow diagram 
2886 Potentially relevant citations identified
From MEDLINE, Embase, Web of Science, 
and reference list of relevant studies
2809 excluded on the basis of title 
and/ or abstract
23 Articles excluded due to:
11 Exposure not relevant
4 Study design not relevant
4 Duplicates
3 Outcome not relevant
1 Risk estimate not estimable
54 Articles included, based on 48 
unique studies
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2 Provide a structured summary including, as applicable, background, objectives, data sources, study 
eligibility criteria, participants, interventions, study appraisal and synthesis methods, results, 
limitations, conclusions and implications of key findings, systematic review registration number 
2 
Introduction 
Rationale 3 Describe the rationale for the review in the context of what is already known Introduction 
Objectives 4 Provide an explicit statement of questions being addressed with reference to participants, 





5 Indicate if a review protocol exists, if and where it can be accessed (such as web address), and, if 




6 Specify study characteristics (such as PICOS, length of follow-up) and report characteristics (such 




7 Describe all information sources (such as databases with dates of coverage, contact with study 
authors to identify additional studies) in the search and date last searched 
Methods 
Search 8 Present full electronic search strategy for at least one database, including any limits used, such that 
it could be repeated 
Supplementary 
Table 3 
Study selection 9 State the process for selecting studies (that is, screening, eligibility, included in systematic review, 




10 Describe method of data extraction from reports (such as piloted forms, independently, in 
duplicate) and any processes for obtaining and confirming data from investigators 
Methods 
Data items 11 List and define all variables for which data were sought (such as PICOS, funding sources) and any 
assumptions and simplifications made 
Methods 
Risk of bias in 
individual 
studies 
12 Describe methods used for assessing risk of bias of individual studies (including specification of 





13 State the principal summary measures (such as risk ratio, difference in means). Methods 
Synthesis of 
results 
14 Describe the methods of handling data and combining results of studies, if done, including 
measures of consistency (such as I2 statistic) for each meta-analysis 
Methods 
Risk of bias 
across studies 
15 Specify any assessment of risk of bias that may affect the cumulative evidence (such as publication 




16 Describe methods of additional analyses (such as sensitivity or subgroup analyses, meta-
regression), if done, indicating which were pre-specified 
Methods 
Results 
Study selection 17 Give numbers of studies screened, assessed for eligibility, and included in the review, with reasons 





18 For each study, present characteristics for which data were extracted (such as study size, PICOS, 
follow-up period) and provide the citations 
Results, Table 1 
Risk of bias 
within studies 
19 Present data on risk of bias of each study and, if available, any outcome-level assessment (see item 
12). 




20 For all outcomes considered (benefits or harms), present for each study (a) simple summary data for 









Risk of bias 
across studies 
22 Present results of any assessment of risk of bias across studies (see item 15) Results; Table 1 
Additional 
analysis 
23 Give results of additional analyses, if done (such as sensitivity or subgroup analyses, meta-





24 Summarise the main findings including the strength of evidence for each main outcome; consider 
their relevance to key groups (such as health care providers, users, and policy makers) 
Discussion 
Limitations 25 Discuss limitations at study and outcome level (such as risk of bias), and at review level (such as 






No Checklist item 
Reported on 
page No 




Funding 27 Describe sources of funding for the systematic review and other support (such as supply of data) 




Supplementary Table 2: MOOSE checklist  
 
Serum albumin, cardiometabolic and other adverse outcomes: systematic review and meta-analyses of 
48 published observational cohort studies involving 1,492,237 participants 
 
Criteria Brief description of how the criteria were handled in the review 
Reporting of background   
 Problem definition A general body of evidence suggests that low serum albumin might 
be associated with increased risk of adverse cardiometabolic 
outcomes, but some of the findings are divergent. 
 Hypothesis statement Serum albumin is associated with risk of several cardiometabolic 
outcomes and other nonvascular outcomes 
 Description of study outcomes Primary outcomes: Cardiovascular disease (CVD), type 2 diabetes, 
metabolic syndrome, and all-cause mortality.  
Secondary outcomes: Hypertension, heart failure, venous 
thromboembolism, dementia, cancer and fracture. 
 Type of exposure  Serum albumin 
 Type of study designs used Observational cohort (prospective or retrospective cohort, case-
cohort or “nested case control”) population-based studies 
 Study population Approximately general populations (i.e., did not select participants 
on the basis of confirmed pre-existing medical conditions such as 
hypertension, cardiovascular disease, liver disease, or chronic kidney 
disease at baseline).  
Reporting of search strategy should include  
 Qualifications of searchers Setor Kunutsor, MD PhD; Samuel Seidu, MD 
 Search strategy, including time 
period included in the synthesis and 
keywords 
Time period: from inception of MEDLINE, EMBASE, Web of 
Science to 30 January 2020.  
Search strategy: 
Supplementary Table 3 
 
 Databases and registries searched MEDLINE, EMBASE, and Web of Science 
 Search software used, name and 
version, including special features 
Ovid was used to search EMBASE 
Reference Manager used to manage references  
 Use of hand searching We searched bibliographies of retrieved papers  
 List of citations located and those 
excluded, including justifications 
Details of the literature search process are outlined in the flow chart.  
The citation list for excluded studies is available upon request. 
 Method of addressing articles 
published in languages other than 
English 
We placed no restrictions on language 
 Method of handling abstracts and 
unpublished studies 
None found 
 Description of any contact with 
authors 
We contacted authors for more information and data on relative risk 
estimates and risk comparisons 
Reporting of methods should include  
 Description of relevance or 
appropriateness of studies assembled 
for assessing the hypothesis to be 
tested 
Detailed inclusion and exclusion criteria are described in the 
Methods section. 
 Rationale for the selection and 
coding of data 
Data extracted from each of the studies were relevant to the 
population characteristics, study design, exposure, outcome, and 
possible effect modifiers of the association. 
 Assessment of confounding We assessed confounding by ranking individual studies on the basis 
of different adjustment levels, and performed sub-group analyses to 
evaluate differences in the overall estimates according to levels of 
adjustment. 
 Assessment of study quality, 
including blinding of quality 
assessors; stratification or regression 
Study quality was assessed based on the nine-star Newcastle–Ottawa 
Scale using pre-defined criteria namely: population 
representativeness, comparability (adjustment of confounders), 
ascertainment of outcome. Sensitivity analyses by several quality 
 
 
on possible predictors of study 
results 
indicators such as study size, duration of follow-up, and adjustment 
factors. 
 Assessment of heterogeneity Heterogeneity of the studies was explored with I2 statistic that 
provides the relative amount of variance of the summary effect due 
to the between-study heterogeneity. 
 Description of statistical methods in 
sufficient detail to be replicated 
Description of methods of meta-analyses, sensitivity analyses, meta-
regression and assessment of publication bias are detailed in the 
methods. We performed random effects meta-analysis with Stata MP 
16. 
 Provision of appropriate tables and 
graphics 
Table 1, Figures 1-4, Supplementary Materials 
Reporting of results should include  
 Graph summarizing individual study 
estimates and overall estimate 
Figure 2-4 
 Table giving descriptive information 
for each study included 
Table 1  
 Results of sensitivity testing 
 
Sensitivity analysis was conducted to assess the influence of each 
individual study by omitting one study at a time and calculating a 
pooled estimate for the remainder of the studies. Results section 
 Indication of statistical uncertainty 
of findings 
95% confidence intervals were presented with all summary 
estimates, I2 values and results of sensitivity analyses 
Reporting of discussion should include  
 Quantitative assessment of bias Sensitivity analyses indicate heterogeneity in strengths of the 
association due to most common biases in observational studies. 
Limitations have been discussed. 
 
 Justification for exclusion All studies were excluded based on the pre-defined inclusion criteria 
in methods section. 
 Assessment of quality of included 
studies 
Brief discussion included in ‘Methods’ section 
Reporting of conclusions should include  
 Consideration of alternative 
explanations for observed results 
Discussed in the context of the results. 
 Generalization of the conclusions Discussed in the context of the results. 
 Guidelines for future research Future studies to replicate results of single reports  




Supplementary Table 3: MEDLINE search strategy 
 
Relevant studies, published before 30 January 2020 (date last searched), were identified through electronic searches not 
limited to the English language using MEDLINE, EMBASE, and the Science Citation Index databases. Electronic 
searches were supplemented by scanning reference lists of articles identified for all relevant studies (including review 
articles), by hand searching of relevant journals and by correspondence with study investigators.  
 
1     exp Serum Albumin/ (79909) 
2     exp Cardiovascular Diseases/ (2301627) 
3     exp Coronary Disease/ (212416) 
4     exp Stroke/ (125186) 
5     exp Myocardial Infarction/ (170626) 
6     exp Death, Sudden, Cardiac/ (14820) 
7     exp Diabetes Mellitus, Type 2/ (124886) 
8     exp Metabolic Syndrome/ (29851) 
9     exp Dementia/ (157281) 
10     exp Mortality/ (364632) 
11     exp Death/ (144169) 
12     exp Neoplasms/ (3214220) 
13     exp Venous Thromboembolism/ (9655) 
14     exp Pulmonary Embolism/ (37773) 
15     fracture.mp. (193505) 
16     exp Hypertension/ (247352) 
17     exp Heart Failure/ (115544) 
18     cohort studies/ or longitudinal studies/ or follow-up studies/ or prospective studies/ or retrospective studies/ or 
cohort.ti,ab. or longitudinal.ti,ab. or prospective.ti,ab. or retrospective.ti,ab. (2449135) 
19     2 or 3 or 4 or 5 or 6 or 8 or 9 or 10 or 11 or 12 or 13 or 14 or 15 or 16 or 17 (5938267) 
20     1 and 18 and 19 (2086) 
21     limit 20 to humans (2061) 
 
******************************* 




Supplementary Table 4: Risk conversion method 
 
To enable a consistent approach to the meta-analysis and enhance interpretation of findings, relative risk estimates for association of 
serum albumin and outcomes that were often differently reported by each study [e.g. per unit or standard deviation (SD) change, 
quintiles, quartiles, or other groupings] were transformed to involve comparisons between the top third and bottom third of each study 
population’s baseline distribution of serum albumin levels using standard statistical methods.1,2 Briefly, assuming a normally distributed 
exposure (e.g. serum albumin) with a linear association with type 2 diabetes risk (i.e. linear relationship between log relative risk 
estimates and levels of the exposure), conversion factors to convert log relative risks from reported scale comparisons to top versus 
bottom third comparisons are derived based on the ratio of expected differences in mean levels of the standardised exposure (i.e. SD 
scale), for the target comparison versus reported comparison. For example, the expected difference in means of the top versus bottom 
thirds of the standard normal distribution is 2.18 SDs, 2.54 SDs for the top versus bottom quartile, and 2.80 SDs for the top versus 
bottom quintile. Hence, relative risk estimates reported for comparisons of extreme quartiles can be converted to comparisons of extreme 
thirds by applying a multiplication conversion factor of 2.18/2.54 to the log relative risk and its standard error and estimates reported 
for comparisons of extreme quintiles can be converted to comparisons of extreme thirds by applying a multiplication conversion factor 
of 2.18/2.80 to the estimates. Similarly, estimates reported per 1 SD can be multiplied by 2.18 to obtain the top versus bottom third 
comparison, and those reported per unit change can be multiplied by 2.18*SD of exposure, to obtain similar comparison. Conversion 





1. Chêne, G and Thompson, SG. Methods for Summarizing the Risk Associations of Quantitative Variables in 
Epidemiologic Studies in a Consistent Form. American Journal of Epidemiology. 1996;144:610-621 
2. Greenland, S and Longnecker, MP. Methods for trend estimation from summarized dose-response data, with applications 
to meta-analysis. American Journal of Epidemiology. 1992;135:1301-1309. 
3. Thompson A and Danesh J. Associations between apolipoprotein B, apolipoprotein AI, the apolipoprotein B/AI ratio and 
coronary heart disease: a literature-based meta-analysis of prospective studies. J Intern Med. 2006;259:481-492 
4. Chowdhury R, Stevens S, Gorman D, Pan A, Warnakula S, Chowdhury S et al. Association between fish consumption, 
long chain omega 3 fatty acids, and risk of cerebrovascular disease: systematic review and meta-analysis. BMJ. 
2012;345:e6698. 
5. Kunutsor SK, Apekey TA, Walley J. Liver aminotransferases and risk of incident type 2 diabetes: a systematic review 






Supplementary Figure 1: Relative risks for type 2 diabetes in individuals in the top versus bottom thirds of 
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Supplementary Figure 2: Relative risks for cardiovascular outcomes in individuals in the top versus bottom 
thirds of baseline levels of serum albumin 
 
Size of data markers are proportional to the inverse of the variance of the relative ratio; CI, confidence interval (bars); 




Supplementary Figure 3: Relative risks for all-cause mortality in individuals in the top versus bottom thirds 
of baseline levels of serum albumin, grouped according to study level characteristics 
 
 




Supplementary Figure 4: Relative risks for all-cause mortality comparing individual with 
hypoalbuminaemia vs normal albumin 
 
 
The summary estimates presented were calculated using random effects models; Size of data markers are proportional to 




Supplementary Figure 5: Relative risks for ischemic stroke, stroke mortality, SCD, nonSCD, and MetS in 
individuals in the top versus bottom thirds of baseline levels of serum albumin 
 




Supplementary Figure 6: Relative risks for venous thromboembolism in individuals in the top versus bottom 
thirds of baseline levels of serum albumin 
 
The summary estimates presented were calculated using fixed effects models; Size of data markers are proportional to 





Supplementary Figure 7: Relative risks for cancer endpoints in individuals in the top versus bottom thirds of 
baseline levels of serum albumin 
 
Size of data markers are proportional to the inverse of the variance of the relative ratio; CI, confidence interval (bars); 





Supplementary Figure 8: Relative risks for fracture, heart failure, hypertension, breast cancer, colon cancer, 
ovarian cancer, all-cause cancer, colorectal cancer death, lung cancer, prostate cancer in individuals in the top 
versus bottom thirds of baseline levels of serum albumin 
 




Supplementary Figure 9: Relative risks for heart failure, cancer, and mild cognitive impairment comparing 
individual with hypoalbuminaemia vs normal albumin 
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The dotted lines show 95% confidence intervals around the overall summary estimate calculated using a fixed effect 























Outcome Nparticipants Ncases Confounders adjusted for 
Quality 
score 
Darne, 1990 Paris Health Centre France 1972-1977 Prospective cohort  40-59 66.2 10.5  NR All-cause mortality 27684 1736 Age and globulin 5 
Gillum, 1992 
National Health and 
Nutrition Examination Survey 
Epidemiologic Follow- 
up Study (NHEFS) USA 1971-1975 Prospective cohort  45-74  NR 15.0  NR All-cause mortality 5765 2399 




Rancho Bernardo Heart and 
Chronic Disease USA 1984-1987 Prospective cohort  50-89  NR 1.4 42.9 All-cause mortality 2342 83 Age and sex 8 
Corti, 1994 
Established Populations for 
Epidemiologic Studies of the 
Elderly (EPESE) USA 1981-1983 Prospective cohort 78.7 36.1 3.7 40.5 All-cause mortality 4116 935 
Age, race, level of education, 
disability status, BMI, smoking, 
chronic conditions 8 
Sahyoun, 1996 Nutrition Status Survey USA 1981-1984 Prospective cohort 74.6  NR NR  41.5 All-cause mortality 287 81 
Age, BUN, TG, history of disease, 
medical conditions preventing 
shopping 6 
Sahyoun, 1996 Nutrition Status Survey USA 1981-1984 Prospective cohort 80.7  NR NR  37.3 All-cause mortality 176 127 
Age, BUN, TG, history of disease, 
medical conditions preventing 
shopping 5 
Huang, 1996 
National Health and Nutrition 
Examination Survey (NHANES I) USA 1971-1975 Prospective cohort  ≥45 0 13.4  NR All-cause mortality 2513 130 
Age, previous fracture hx, menopausal 
status, physical activity, parity, and 
alcohol use 8 
Weijenberg, 
1997 Zutphen Elderly Study Netherlands 1985 Prospective cohort 71.4 100 5.0 44.1 All-cause mortality 820 189 
Age, BMI, DBP, TC, HDL-C, 
smoking, alcohol consumption, health 
status 6 
Reuben, 2000 Iowa 65+ Rural Health Study USA 1987-1989 Case cohort 77.5 41.5 4.0  NR All-cause mortality 632 171 
Age, gender, educational level, recent 
weight loss, body mass index, 
smoking, myocardial infarction or 
stroke history, and diabetes history 8 
Djousse, 2002 Framingham Offspring USA 1971 Prospective cohort 37.6 48 21.9  NR All-cause mortality 4506 499 
Age, BMI, TC, HDL-C, alcohol 
consumption, cigarette smoking, 
serum bilirubin, and blood pressure 8 
Hu, 2003 
Mac-Arthur Research Network 
Study of Successful Aging 
(substudy of EPESE) USA 1988 Prospective cohort 74.3 47 7.0 40.9 All-cause mortality 870 197 
Age, sex, race, markers of 
inflammation and undernutrition, 
history of CAD, hypertension, DM, 
depression score, smoking status, 
alcohol consumption, and lipid-
lowering medications 8 
Shaper, 2004 
British Regional Heart Study 
(BRHS) UK 1978-1980 Prospective cohort  40-59 100 16.8 44.6 All-cause mortality 7690 1511 
Age, smoking, physical activity, 
social class, BMI, pre-existing 
CHD/stroke, use of antihypertensive 
treatment, FEV1, SBP, and TC 7 
              
Ansai, 2007 8020 Data Bank Survey Japan 1997-1998 Prospective cohort 80.0 39.7 4.0  NR All-cause mortality 697 108 
Gender, smoking status, physical 
health, status, BMI, TC 7 
Okamura, 2008 
National Integrated Project for 
Prospective Observation of Non-
communicable Disease Japan 1980 Prospective cohort  60-74 43.2 12.4 42.6 All-cause mortality 1844 439 
Age, TC, DM, hypertension, BMI, 




















Outcome Nparticipants Ncases Confounders adjusted for 
Quality 
score 
and Its Trends in the Aged 
(NIPPON DATA80) 
Carriere, 2008 
Pathologies Oculaires Lie´es a` 
l’Age Study France 1995-1997 Prospective cohort 70.0 38.4 9.0 41.3 All-cause mortality 1441 221 
Age, educational level, perceived 
health, and smoking 7 
Grimm, 2009 General Hospital Vienna Austria 1992-2002 Prospective cohort 49.9 45 7.4  NR All-cause mortality 285930 48139 Age and gender 7 
Takata, 2012 Niigata City Japan 1998 Prospective cohort 70.0 50.7 10.0 43.1 All-cause mortality 600 80 Gender, smoking, ADL 7 
Sidorenkov, 
2012 Northwest Russia Russia 1999-2000 Prospective cohort  ≥18 53.1 10.2 43.4 All-cause mortality 3704 242 
Age, education, smoking, frequency 
of taking >80g alcohol on occasion, 
physical activity, DBP, ApoB/ApoA1 
ratio, BMI, history of CVD 8 
Hu, 2013 
National Health and Nutrition 
Examination Survey (NHANES III) USA 1988-1994 Prospective cohort 47.0 47 13.0  NR All-cause mortality 18162 4610 Age, sex 8 
Hu, 2013 Life Insurance Data USA   Prospective cohort 42.0 64 4.5  NR All-cause mortality 311535 837 Age, sex 7 
Liu, 2015 Rugao longevity cohort China 2007-2008 Prospective cohort 97.0 22.2 6.0 42.4 All-cause mortality 433 394 
Age, sex, TG, LDL-C, platelet count, 
lymphocyte count, and neutrophil 
count 8 
Umeki, 2016 Tanushimaru Study Japan 1999 Prospective cohort 62.6 41.1 15.0 44.0 All-cause mortality 1905 337 Age, sex, HDL-C, LDL-C, TG, eGFR 8 
Wu, 2018 
Tapei City Geriatric Health 
Examination Program Taiwan 2006-2010 Prospective cohort 73.1 50.8 3.3 43.0 All-cause mortality 77531 3840 
Age, sex, education level, marital 
status, BMI, smoking, alcohol 
consumption, regular exercise, 
cognitive status, mood disease, eGFR, 
ALT, anemia, hypertension, DM, 
hyperlipidemia, CVD, chronic 
inflammatory diseases, and history of 
cancer 7 
Schalk, 2006 
Longitudinal Aging Study 
Amsterdam (LASA) Netherlands 1992-1993 Prospective cohort 74.3  NR 6.0  NR CVD 713 86 
Age, sex, education, smoking, alcohol 
consumption, BMI, PA, DM, DBP, 
SBP, cognitive impairment, and TC 8 
Hayward, 2017 RCGP-RSC database UK   Prospective cohort  18-90 40.1 9.0   CVD 113993 2369 
 Multivariate model, but covariates 
not specified 8 
Kuller, 1991 
Multiple Risk Factor Intervention 
Trial (MRFIT) USA 1973-1976 Nested case control 47.0 100 10.5 45.0 CHD mortality + MI 615 205 Age, DBP, smoking, TC 7 
Vazquez-Oliva, 
2018 
Registre GIronı´ del COR 
(REGICOR) Study Spain 2005 Case cohort 55.3 49.8 5.0 42.1 CHD 775 105 
Age, sex, smoking, DM, SBP, DBP, 
TC, and HDL-C 8 
Xu, 2014 Northern Manhattan Study USA 1993-2001 Prospective cohort 69.0 37.2 12.0 44.2 Stroke 2986 329 
Age, sex, race-ethnicity, BMI, 
moderate alcohol drinking, DM, 
hypercholesterolemia, WBC count, 
eGFR, and history of AF 8 
Gopal, 2010 
The Health, Aging, and Body 
Composition Study (Health ABC) USA 1997-1998 Prospective cohort 73.6 48 9.4 39.8 HF 2907 342 
Age, history of CHD, SBP, history of 
smoking, creatinine, heart rate, fasting 
glucose, LVH, interleukin-6, CRP, 
tumor necrosis factor-α, incident CHD 8 
Filippatos, 2011 Cardiovascular Health Study (CHS) USA 
1989-
1990/1992-
1993 Prospective cohort 73.1 42.4 9.6 40.0 HF 5450 260 
 58 covariates based on 
sociodemographic characteristics and 
prevalent medical conditions 9 
Oda, 2014 Medical Check-up Center Japan 2008-2009 Retrospective cohort 49.8 61.8 3.1 43.0 Hypertension 2240 331 
sex, age, current smoking, everyday 




















Outcome Nparticipants Ncases Confounders adjusted for 
Quality 
score 
creatinine, uric acid, fasting glucose, 
log TG, log high-sensitivity CRP, 
WBC count, hemoglobin, DBP 
Stranges, 2008 Western New York Study (WNYS) US 1996-2001 Prospective cohort 59.0 52.5 5.9 43.4 Type 2 diabetes 219 61 
Age, family history of diabetes, 
smoking, drinking status, and BMI 7 
Abbasi, 2012 
European Prospective Investigation 
Into Cancer and 
Nutrition (EPIC)-Netherlands 
the 
Netherlands 1993-1997 Prospective cohort 49.1 25.7 10.2 38.9 Type 2 diabetes 38379 924 age, DM risk factors 9 
Abbasi, 2012 
Prevention of Renal and Vascular 
End-stage Disease (PREVEND) 
the 
Netherlands 1997-1998 Prospective cohort 48.9 49.1 7.7 45.8 Type 2 diabetes 7952 503 age, DM risk factors 9 
Bae, 2013 Total Healthcare Center Korea 2005-2009 Prospective cohort 44.6 73.7 4.0 45.5 Type 2 diabetes 9029 556 
Age, triglyceride, HDL-C, LDL-C, 
SBP, BMI, presence of IFG and fatty 
liver, smoking status, and alcohol 
consumption. 8 
              
Liu, 2017 Chinese PLA general hospital China 2009-2013 Retrospective cohort 71.0 100 4.0 44.3 Type 2 diabetes 18384 450 
Age, marital status, current smoking, 
current alcohol drinking, BMI, 
baseline FPG, baseline 2hPG, baseline 
eGFR, baseline prevalence and 
treatment status of hypertension and 
dyslipidemia 6 
Hwang, 2018 
Health Promotion Center of 
Samsung Medical Center Korea 2006-2012 Retrospective cohort 51.0 56.8 5.0  NR Type 2 diabetes 15428 599 
Age, sex, BMI, smoking status, SBP, 
FPG, HbA1c, TG, LDL-C, HDL-C, 
CRP, percent body weight change, 
serum insulin 8 
Hu, 2020 Xiaotangshan hospital in Beijing China 2009-2016 Prospective cohort 41.0 57.9 3.0 44.9 Type 2 diabetes 30442 1634 
Age, sex, heart rate, systolic blood 
pressure and levels of serum uric acid, 
TC, TG, HDL-C and ALT, white cell 
count, eGFR, FPG, BMI 8 
Folsom, 2010 
Atherosclerosis Risk in 
Communities (ARIC) USA 1987-1989 Prospective cohort 54.2 45.1 16.9 38.7 VTE 15300 462 
Age, sex, race, HRT use, race, 
diabetes status, history of cancer, 







REasons for Geographic And Racial 
Differences in Stroke (REGARDS) USA 2003-2007 Prospective cohort  ≥45  NR 4.6 42.0 VTE 30239 268 
Age, sex, race, region, race*region 
interaction, BMI, smoking, 
hypertension, DM, history of CHD or 
stroke 8 
              
Ko, 1994 Washington County USA 1974 Nested case control  NR 34.7  NR 41.3 Colon cancer 236 118 Age, sex 6 
Knekt, 2000 Finnish Mobile Clinic Finland 1968-1972 Nested case control 53.6 46.3 23.0 46.3 Colorectal cancer 465 177 Age, sex, municipality 8 
Merriel, 2016 
Clinical Practice 
Research Datalink (CPRD) UK 2003-2007 Prospective cohort 76.5 48.6 1.0 41.2 Cancer 100122 15540 
Age, gender and history of 
chest/abdominal trauma, sepsis, liver 
failure, HF or nephrotic syndrome 5 
Ghuman, 2017 
Apolipoprotein Mortality Risk 
Study (AMORIS)  Sweden 1986-1999 Prospective cohort 45.8  NR 18.0 43.3 
Colorectal cancer 
death 325599 4764 
Age, sex, education, SES, Charlson 
comorbidity index, UC, glucose, TC 
























European Prospective Investigation 
Into Cancer and 
Nutrition (EPIC)-Heidelberg Germany 1994-1998 Case cohort 52.6 46.5 11.8 46.0 Cancer mortality 5132 761 
Age, smoking, alcohol intake, current 
aspirin use, physical activity, WC, 
BMI, height, education level 9 
Schwartz, 2017 Janus Serum Bank Cohort Norway 1978-2004 Nested case control 42.6   28.5 51.0 Ovarian cancer 404 202 Age, height, BMI 8 
              
Wang, 2018 
Tianjin Medical University General 
Hospital China 2008-2009 Retrospective cohort 72.1 75.4 7.0 44.1 
Mild cognitive 
impairment 1800 196 
Sex, age, race, BMI, medical history, 
medicine history, CRP, uric acid and 
total bilirubin 7 
Kunutsor, 2019 
Kuopio Ischemic Heart Disease 
(KHID) Finland 1984-1989 Prospective cohort 53.0 100 25.6 42.3 Fracture 2245 121 
Age, BMI, SBP, history of 
hypertension, prevalent CHD, 
smoking, physical activity, history of 
T2D, eGFR, SES, dietary energy 
intake, serum ionized calcium, CRP 8 
              
 
AF, atrial fibrillation; ApoB, apolipoprotein B; ApoA1, Apolipoprotein A1; aPTT, activated partial thromboplastin time; ALT, alanine aminotransferase; BMI, body mass index; BUN, blood urea nitrogen; CAD, coronary artery disease; CHD, coronary heart disease; CRP, 
C-reactive protein; CVD, cardiovascular disease; DBP, diastolic blood pressure; DM, diabetes mellitus; eGFR, estimated glomerular filtration rate; FEV1, forced expiratory volume; FPG, fasting plasma glucose; HDL-C, high density lipoprotein cholesterol; HF, heart failure; 
IFG, impaired fasting glucose; LDL-C, low density lipoprotein cholesterol; LVH, left ventricular hypertrophy; MI, myocardial infarction; PA, physical activity; SES, socioeconomic status; SBP, systolic blood pressure; T2D, type 2 diabetes; TC, total cholesterol; TG, 
triglycerides; UC, ulcerative colitis; WBC, white blood cell; VTE, venous thromboembolism; WC, waist circumference 
 
 
 
 
